$RARE
Ultragenyx Pharmaceutical Inc.

2020 Q3 Form 10-Q Financial Statement

#000156459020047991 Filed on October 27, 2020

View on sec.gov

Income Statement

Concept 2020 Q3 2019 Q4 2019 Q3
Revenue $81.47M $35.59M $25.80M
YoY Change 215.78% 118.89% 119.33%
Cost Of Revenue $2.350M $5.110M $2.680M
YoY Change -12.31% 901.96% 881.68%
Gross Profit $79.12M $30.49M $23.12M
YoY Change 242.21% 93.59% 101.22%
Gross Profit Margin 97.12% 85.66% 89.61%
Selling, General & Admin $42.12M $41.88M $41.01M
YoY Change 2.72% 21.46% 31.87%
% of Gross Profit 53.24% 137.36% 177.36%
Research & Development $87.31M $83.06M $100.1M
YoY Change -12.81% 15.97% 42.98%
% of Gross Profit 110.36% 272.42% 433.15%
Depreciation & Amortization $3.090M $2.170M $2.140M
YoY Change 44.39% -26.19% -50.92%
% of Gross Profit 3.91% 7.12% 9.26%
Operating Expenses $131.8M $130.0M $143.8M
YoY Change -8.38% 21.99% 41.83%
Operating Profit -$50.32M -$99.56M -$118.0M
YoY Change -57.37% 9.58% 31.67%
Interest Expense -$10.18M $4.190M $5.490M
YoY Change -285.43% 59.32% 101.1%
% of Operating Profit
Other Income/Expense, Net $547.0K -$980.0K -$153.0K
YoY Change -457.52% -9900.0% 2.0%
Pretax Income -$68.53M -$91.24M -$112.7M
YoY Change -39.19% 4.04% 29.45%
Income Tax $313.0K $2.560M $290.0K
% Of Pretax Income
Net Earnings -$68.85M -$93.81M -$113.0M
YoY Change -39.07% 6.81% 29.42%
Net Earnings / Revenue -84.5% -263.55% -437.96%
Basic Earnings Per Share -$1.13
Diluted Earnings Per Share -$1.13 -$1.622M -$1.958M
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q3 2019 Q4 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $765.5M $755.2M $527.1M
YoY Change 45.23% 64.29% 4.77%
Cash & Equivalents $197.5M $433.6M $122.6M
Short-Term Investments $568.0M $321.6M $404.5M
Other Short-Term Assets $64.20M $51.40M $49.20M
YoY Change 30.49% 19.81% -1.01%
Inventory $14.46M $11.55M $14.14M
Prepaid Expenses
Receivables $27.80M $32.84M $23.10M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $872.0M $851.0M $613.5M
YoY Change 42.14% 62.91% 8.11%
LONG-TERM ASSETS
Property, Plant & Equipment $86.40M $44.35M $63.60M
YoY Change 35.85% 121.23% 221.21%
Goodwill $44.41M
YoY Change 0.0%
Intangibles $129.0M
YoY Change -0.17%
Long-Term Investments $129.3M $32.90M $26.30M
YoY Change 391.63%
Other Assets $5.092M $3.471M $3.100M
YoY Change 64.26% -1.22% -3.13%
Total Long-Term Assets $396.4M $284.5M $266.4M
YoY Change 48.79% 44.27% 34.82%
TOTAL ASSETS
Total Short-Term Assets $872.0M $851.0M $613.5M
Total Long-Term Assets $396.4M $284.5M $266.4M
Total Assets $1.268B $1.135B $879.9M
YoY Change 44.15% 57.8% 15.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $10.85M $12.87M $13.50M
YoY Change -19.63% 4.86% 64.63%
Accrued Expenses $79.65M $83.19M $69.56M
YoY Change 14.51% 33.22% 18.9%
Deferred Revenue $102.9M $16.00K
YoY Change 643012.5%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $201.2M $103.3M $90.30M
YoY Change 122.81% 38.24% 35.38%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $367.7M $345.1M $31.20M
YoY Change 1078.53% 7151.52% 563.83%
Total Long-Term Liabilities $367.7M $345.1M $31.20M
YoY Change 1078.53% 7151.52% 563.83%
TOTAL LIABILITIES
Total Short-Term Liabilities $201.2M $103.3M $90.30M
Total Long-Term Liabilities $367.7M $345.1M $31.20M
Total Liabilities $602.2M $481.7M $152.7M
YoY Change 294.36% 335.37% 48.98%
SHAREHOLDERS EQUITY
Retained Earnings -$1.433B
YoY Change 39.09%
Common Stock $58.00K
YoY Change 13.73%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $666.2M $653.8M $727.3M
YoY Change
Total Liabilities & Shareholders Equity $1.268B $1.135B $879.9M
YoY Change 44.15% 57.8% 15.0%

Cashflow Statement

Concept 2020 Q3 2019 Q4 2019 Q3
OPERATING ACTIVITIES
Net Income -$68.85M -$93.81M -$113.0M
YoY Change -39.07% 6.81% 29.42%
Depreciation, Depletion And Amortization $3.090M $2.170M $2.140M
YoY Change 44.39% -26.19% -50.92%
Cash From Operating Activities -$61.97M -$72.04M -$88.50M
YoY Change -29.98% 28.97% 27.98%
INVESTING ACTIVITIES
Capital Expenditures -$6.050M -$11.50M -$5.030M
YoY Change 20.28% 858.33% 388.35%
Acquisitions
YoY Change
Other Investing Activities -$89.70M $78.76M $84.35M
YoY Change -206.34% 5.36% 389.27%
Cash From Investing Activities -$95.76M $67.27M $79.31M
YoY Change -220.74% -8.55% 389.27%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 19.13M 315.4M 900.0K
YoY Change 2025.56% 2477.21% -96.4%
NET CHANGE
Cash From Operating Activities -61.97M -72.04M -88.50M
Cash From Investing Activities -95.76M 67.27M 79.31M
Cash From Financing Activities 19.13M 315.4M 900.0K
Net Change In Cash -138.6M 310.7M -8.290M
YoY Change 1571.89% 937.68% -70.31%
FREE CASH FLOW
Cash From Operating Activities -$61.97M -$72.04M -$88.50M
Capital Expenditures -$6.050M -$11.50M -$5.030M
Free Cash Flow -$55.92M -$60.54M -$83.47M
YoY Change -33.01% 10.76% 22.53%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q3 us-gaap Restricted Cash And Cash Equivalents Current Asset Statement Of Financial Position Extensible List
RestrictedCashAndCashEquivalentsCurrentAssetStatementOfFinancialPositionExtensibleList
us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember
CY2019Q3 us-gaap Restricted Cash And Cash Equivalents Current Asset Statement Of Financial Position Extensible List
RestrictedCashAndCashEquivalentsCurrentAssetStatementOfFinancialPositionExtensibleList
us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember
CY2020Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent Asset Statement Of Financial Position Extensible List
RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList
us-gaap:OtherNoncurrentAssetsMember
CY2019Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent Asset Statement Of Financial Position Extensible List
RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList
us-gaap:OtherNoncurrentAssetsMember
CY2020Q3 rare Investment In Equity Securities
InvestmentInEquitySecurities
129320000
CY2019Q4 us-gaap Long Term Investments
LongTermInvestments
5174000
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
37597000
CY2020Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5092000
CY2020Q3 us-gaap Assets
Assets
1268385000
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
10850000
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
79653000
CY2020Q3 rare Contract Liabilities Current
ContractLiabilitiesCurrent
102898000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
7235000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
103300000
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
36668000
CY2020Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
33306000
CY2019Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
33306000
CY2020Q3 rare Liability Related To Sale Of Future Royalties
LiabilityRelatedToSaleOfFutureRoyalties
331034000
CY2019Q4 rare Liability Related To Sale Of Future Royalties
LiabilityRelatedToSaleOfFutureRoyalties
315369000
CY2020Q3 us-gaap Liabilities
Liabilities
602194000
CY2019Q4 us-gaap Liabilities
Liabilities
481732000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
30328000
CY2019Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
129000000
CY2019Q4 us-gaap Goodwill
Goodwill
44406000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
280984000
CY2020Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
42123000
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
60815690
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
60815690
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
57838220
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
57838220
rare Cost Of Sales
CostOfSales
648000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
100144000
CY2019Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
41006000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
131891000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
131785000
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
143833000
us-gaap Operating Expenses
OperatingExpenses
413523000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-50315000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-118033000
us-gaap Operating Income Loss
OperatingIncomeLoss
-234035000
CY2020Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1338000
CY2019Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
3319000
us-gaap Investment Income Interest
InvestmentIncomeInterest
6054000
CY2020Q3 us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-11520000
CY2019Q3 us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
2166000
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
91348000
CY2020Q3 rare Non Cash Interest Expense On Liability Related To Sale Of Future Royalties
NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties
8582000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
547000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1137000
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.13
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.96
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.73
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.50
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
60687177
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
57707694
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
59564163
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
56161996
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-68845000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-112994000
us-gaap Net Income Loss
NetIncomeLoss
-162555000
us-gaap Net Income Loss
NetIncomeLoss
-308922000
CY2020Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
374000
CY2019Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-234000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
414000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-79000
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-645000
CY2019Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-92000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
746000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
641000
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-271000
CY2019Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-326000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1160000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
562000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-69116000
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-113320000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-161395000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-308360000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
695587000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
20527000
CY2020Q3 rare Issuance Of Common Stock Under Equity Plan Awards Net Of Tax
IssuanceOfCommonStockUnderEquityPlanAwardsNetOfTax
19193000
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-271000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-68845000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
666191000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
653764000
rare Issuance Of Common Stock Value In Connection With License Agreement
IssuanceOfCommonStockValueInConnectionWithLicenseAgreement
55268000
rare Stock Issued During Period Value At Market Offering
StockIssuedDuringPeriodValueAtMarketOffering
20391000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
63112000
rare Issuance Of Common Stock Upon Exercise Of Warrants And Under Equity Plan Awards Net Of Tax
IssuanceOfCommonStockUponExerciseOfWarrantsAndUnderEquityPlanAwardsNetOfTax
35051000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1160000
us-gaap Net Income Loss
NetIncomeLoss
-162555000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
666191000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
819787000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
19894000
CY2019Q3 rare Issuance Of Common Stock Under Equity Plan Awards Net Of Tax
IssuanceOfCommonStockUnderEquityPlanAwardsNetOfTax
904000
CY2019Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-326000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-112994000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
727265000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
608908000
rare Stock Issued During Period Value Secondary Issues
StockIssuedDuringPeriodValueSecondaryIssues
330415000
rare Stock Issued During Period Value At Market Offering
StockIssuedDuringPeriodValueAtMarketOffering
24828000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
62854000
rare Issuance Of Common Stock Under Equity Plan Awards Net Of Tax
IssuanceOfCommonStockUnderEquityPlanAwardsNetOfTax
8620000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
562000
us-gaap Net Income Loss
NetIncomeLoss
-308922000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
727265000
us-gaap Profit Loss
ProfitLoss
-162555000
us-gaap Profit Loss
ProfitLoss
-308922000
rare Allocated Share Based Compensation Expense Net Of Capitalized Inventory Cost
AllocatedShareBasedCompensationExpenseNetOfCapitalizedInventoryCost
62897000
rare Allocated Share Based Compensation Expense Net Of Capitalized Inventory Cost
AllocatedShareBasedCompensationExpenseNetOfCapitalizedInventoryCost
62335000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-217000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
4931000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
9128000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
6370000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-167000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-925000
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
91348000
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
11994000
rare Non Cash Collaboration Royalty Revenue
NonCashCollaborationRoyaltyRevenue
9428000
rare Non Cash Interest Expense On Liability Related To Sale Of Future Royalties
NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties
25093000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
28000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-220000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-5126000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
10402000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2635000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
6604000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
12461000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
5874000
rare Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOFUseAssets
7261000
rare Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOFUseAssets
15581000
rare Increase Decrease In Accounts Payable Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherOperatingLiabilities
2822000
rare Increase Decrease In Accounts Payable Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherOperatingLiabilities
4043000
rare Increase Decrease In Contract Liabilities
IncreaseDecreaseInContractLiabilities
102898000
rare Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
7600000
rare Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
17071000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-69768000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-273344000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
21959000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
13332000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
648524000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
610267000
us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
10220000
us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
14339000
us-gaap Payments To Acquire Notes Receivable
PaymentsToAcquireNotesReceivable
1880000
us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
40390000
us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
35100000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
367446000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
522533000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
2275000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-277022000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-80305000
rare Proceeds From Issuance Of Common Stock In Connection With License Agreement
ProceedsFromIssuanceOfCommonStockInConnectionWithLicenseAgreement
55268000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
330415000
rare Proceeds From Issuance Of Common Stock At Market Offering
ProceedsFromIssuanceOfCommonStockAtMarketOffering
20391000
rare Proceeds From Issuance Of Common Stock At Market Offering
ProceedsFromIssuanceOfCommonStockAtMarketOffering
24828000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
35051000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
8620000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
149000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
110561000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
363863000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
239000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-502000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-235990000
CY2020Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1921000
CY2019Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2499000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
200254000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
125237000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
9712000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
436244000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
115525000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
200254000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
125237000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
13195000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
21515000
us-gaap Nature Of Operations
NatureOfOperations
<div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Organization </p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ultragenyx Pharmaceutical Inc. (the Company) is a biopharmaceutical company incorporated in California on April 22, 2010. The Company subsequently reincorporated in the state of Delaware in June 2011.</p> <p style="margin-top:4pt;margin-bottom:0pt;text-indent:5%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. The Company has four approved therapies. Crysvita<span style="font-weight:bold;">®</span> (burosumab) is approved in the United States by the U.S. Food and Drug Administration (FDA) and in Canada for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients one year of age and older, and has received European conditional marketing authorization for the treatment of XLH with radiographic evidence of bone disease in children one year of age and older and adolescents with growing skeletons. In October 2020, this authorization was expanded to include older adolescents and adults. In Brazil, Crysvita is approved for treatment of XLH in adult and pediatric patients one year of age and older. <span style="color:#000000;">Crysvita was approved by the FDA on June 18, 2020 for the treatment of FGF23-related hypophosphatemia in tumor-induced osteomalacia (TIO), associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized in adults and pediatric patients 2 years of age and older. </span></p> <p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has also received FDA approval for Mepsevii™ (vestronidase alfa), the first medicine approved for the treatment of children and adults with mucopolysaccharidosis VII (MPS VII), also known as Sly syndrome. In the European Union and the United Kingdom, Mepsevii is approved under exceptional circumstances for patients of all ages for the treatment of non-neurological manifestations of MPS VII. In Brazil, Mepsevii is approved for the treatment of MPS VII for patients of all ages. </p> <p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dojolvi, formerly known as UX007, was approved by FDA on June 30, 2020 for the treatment of pediatric and adult patients severely affected by long-chain fatty acid oxidation disorders (LC-FAOD). </p> <p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the approved treatments, the Company has two ongoing clinical development programs. DTX301 is an adeno-associated virus 8 (AAV8) gene therapy product candidate in development for the treatment of patients with ornithine transcarbamylase (OTC) deficiency, the most common urea cycle disorder; and DTX401 is an AAV8 gene therapy product candidate for the treatment of patients with glycogen storage disease type Ia (GSDIa). The Company operates as one reportable segment.</p> <p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has sustained operating losses and expects such annual losses to continue over the next several years. The Company’s ultimate success depends on the outcome of its research and development and commercialization activities, for which it expects to incur additional losses in the future. Management recognizes that the Company will likely need to raise additional capital to fully implement its business plans. Through September 30, 2020, the Company has relied primarily on the proceeds from equity offerings and its sale of future royalties to finance its operations.</p> <p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will likely raise additional capital through the issuance of equity, borrowings, or strategic alliances with partner companies. However, if such financing is not available at adequate levels, the Company would need to reevaluate its operating plans.</p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:13pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements have been prepared in accordance with GAAP. The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities and the reported amounts of expenses in the consolidated financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to clinical trial accruals, fair value of assets and liabilities, income taxes, stock-based compensation, and the liability related to the sale of future royalties. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. </p>
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
197486000
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
122577000
CY2020Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
847000
CY2019Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
161000
CY2020Q3 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
875497000
CY2019Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
768920000
CY2020Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
745892000
CY2020Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
912000
CY2020Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
7000
CY2020Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
746797000
CY2019Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
741009000
CY2019Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
172000
CY2019Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
13000
CY2019Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
741168000
us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2020Q3 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2019Q3 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2020Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
10211000
CY2019Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
8191000
CY2020Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
4246000
CY2019Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
3355000
CY2020Q3 us-gaap Inventory Net
InventoryNet
14457000
CY2019Q4 us-gaap Inventory Net
InventoryNet
11546000
CY2020Q3 rare Research Clinical Study And Manufacturing Expenses
ResearchClinicalStudyAndManufacturingExpenses
20486000
CY2019Q4 rare Research Clinical Study And Manufacturing Expenses
ResearchClinicalStudyAndManufacturingExpenses
22894000
CY2020Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
43008000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
41324000
CY2020Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
16159000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
18976000
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
79653000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
83194000
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
81470000
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
25800000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
179488000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
68121000
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
81470000
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
25800000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
179488000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
68121000
CY2018Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
2979000
rare Contract With Customer Liability Additions During Period
ContractWithCustomerLiabilityAdditionsDuringPeriod
-154621000
rare Contract With Customer Liability Additions During Period
ContractWithCustomerLiabilityAdditionsDuringPeriod
452000
rare Contract With Customer Liability Deductions During Period
ContractWithCustomerLiabilityDeductionsDuringPeriod
-51723000
rare Contract With Customer Liability Deductions During Period
ContractWithCustomerLiabilityDeductionsDuringPeriod
3447000
CY2020Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
102898000
CY2019Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
16000
CY2020Q3 rare Percentage Of Gross Accounts Receivable Balance
PercentageOfGrossAccountsReceivableBalance
0.83
CY2019Q4 rare Percentage Of Gross Accounts Receivable Balance
PercentageOfGrossAccountsReceivableBalance
0.87
CY2019 us-gaap Proceeds From Royalties Received
ProceedsFromRoyaltiesReceived
314234000
CY2019 rare Non Cash Interest Expense On Liability Related To Sale Of Future Royalties
NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties
1135000
CY2019Q4 rare Liability Related To Sale Of Future Royalties
LiabilityRelatedToSaleOfFutureRoyalties
315369000
rare Non Cash Collaboration Royalty Revenue
NonCashCollaborationRoyaltyRevenue
9428000
rare Non Cash Interest Expense On Liability Related To Sale Of Future Royalties
NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties
25093000
CY2020Q3 rare Liability Related To Sale Of Future Royalties
LiabilityRelatedToSaleOfFutureRoyalties
331034000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
20341000
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
19907000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
62922000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
62335000
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8662701
CY2019Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8338200
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8696942
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8104911
CY2020Q3 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
108000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
-306000
CY2020Q3 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
905000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
159000
CY2020Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1013000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-147000

Files In Submission

Name View Source Status
0001564590-20-047991-index-headers.html Edgar Link pending
0001564590-20-047991-index.html Edgar Link pending
0001564590-20-047991.txt Edgar Link pending
0001564590-20-047991-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g22m0czn2xbf000001.jpg Edgar Link pending
gqduqx1offjd000001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
rare-10q_20200930.htm Edgar Link pending
rare-10q_20200930_htm.xml Edgar Link completed
rare-20200930.xsd Edgar Link pending
rare-20200930_cal.xml Edgar Link unprocessable
rare-20200930_def.xml Edgar Link unprocessable
rare-20200930_lab.xml Edgar Link unprocessable
rare-20200930_pre.xml Edgar Link unprocessable
rare-ex105_443.htm Edgar Link pending
rare-ex311_10.htm Edgar Link pending
rare-ex312_8.htm Edgar Link pending
rare-ex321_9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending